SAB Biotherapeutics, Inc. (SABS)
$2.68-5.30%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $26M
- Beta
- 0.58
- P/E (TTM)
- 0.75
- Short % float
- 54.20%
- Days to cover
- 5.0
- SI change
- +19.1%
- 1W
- -8.53%
- 1M
- -22.54%
- vs SPY 1W
- -8.39%
- vs SPY 1M
- -25.05%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SABS?
- LOPJLB’s latest quantitative signal on SAB Biotherapeutics, Inc. (SABS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SABS in?
- SAB Biotherapeutics, Inc. (SABS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does SAB Biotherapeutics, Inc. (SABS) do?
- SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabete…